Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | S100B | P04271 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767306 | 0.81 | MAOB (0.64) | ACHEALDH1A1MAPTGAAS100B | |
| SCHEMBL17471435 | 0.81 | MAPT (0.51) | ACHEALDH1A1MAPTGAAMAOB | |
| SCHEMBL9441709 | 0.80 | MAOB (0.48) | ALDH1A1MAPTGAAMAOBKMT2A | |
| SCHEMBL9441715 | 0.80 | MAOB (0.48) | ALDH1A1MAPTGAAMAOBKMT2A | |
| SCHEMBL994961 | 0.78 | MAOB (0.66) | ALDH1A1MAPTGAAS100BMAOB | |
| SCHEMBL994960 | 0.78 | MAOB (0.66) | ALDH1A1MAPTGAAS100BMAOB | |
| SCHEMBL11380636 | 0.76 | S100B (0.72) | ACHEALDH1A1MAPTGAAS100B | |
| SCHEMBL16488576 | 0.76 | S100B (0.72) | ACHEALDH1A1MAPTGAAS100B | |
| SCHEMBL13038178 | 0.76 | S100B (0.72) | ACHEALDH1A1MAPTGAAS100B | |
| SCHEMBL269057 | 0.76 | S100B (0.72) | ACHEALDH1A1MAPTGAAS100B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707132-B1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | UNIV PARIS SACLAY (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | Universite Paris-Saclay (FR) | 2021-06-15 | — | — | US | disclosed |
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | Universite Paris-Saclay (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | ADH1C, ADH1A, ADH5 | ACHE 1378/4885ALDH1A1 179/4885MAPT 2186/4885 |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | ADH1C, PNMT, ADH1A | ACHE 1421/4885ALDH1A1 182/4885MAPT 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.